AUTHORS
Monika Kulasekaran, MD, Elias Jabbour, MD2, Nicholas Short, MD3, Abhishek Maiti, MBBS4, Musa Yilmaz, MD5, Hannah Goulart, MD6, Partow Kebriaei, MD7, Md Islam, MD, MPH8, Rebecca Garris9, Hagop Kantarjian, MD10, Nitin Jain, MD11
AFFILIATIONS
1 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background
CD19-directed chimeric antigen receptor (CAR) T cell therapies, such as brexucabtagene autoleucel (brexu-cel) and obecabtagene autoleucel (obe-cel), have transformed the treatment paradigm for adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). In the pivotal ZUMA-3 and FELIX trials, response rates of 70-80% were noted in heavily pretreated adult patients (pts) with R/R B-ALL. However, several pts relapse post CD19 CAR T, often maintaining CD19 antigen expression. Whether a second CD19 CAR T would be effective in this clinical scenario is largely unexamined.
Methods
We performed a retrospective analysis of adult pts who received a second CD19 CAR T at our institution for R/R B-ALL.
Results
We identified 6 pts (4 male; median age 38, range, 26–69) with B-ALL who underwent a second CD19 CAR T infusion. All 6 pts received CAR T outside of clinical trials (as standard of care therapy). All pts had both blinatumomab and inotuzumab exposure prior to CAR1. All 6 pts had Ph negative B-ALL, including 2 pts with CRLF2 rearrangements and 1 pt with EPOR fusion. Five pts received brexu-cel as first CAR T (CAR1) followed by obe-cel as second CAR T (CAR2). One pt received brexu-cel as CAR1 and CAR2. The median interval between CAR1 and CAR2 was 18.2 months (range, 10-36 months). Prior to CAR1, all pts were in morphologic remission.
Four of the 6 pts underwent allogeneic stem cell transplantation (allo-SCT) between CAR1 and CAR2 (2 pts had allo-SCT as post-CAR1 consolidation; 2 had allo-SCT after disease relapse post-CAR1). One additional pt had allo-SCT prior to CAR1.
At CAR2 infusion, all 6 pts were in morphologic remission (4 pts were MRD-positive by NGS; 2 pts were NGS MRD negative). Post-CAR-T2, all 6 pts achieved NGS MRD-negativity at Day 28 evaluation. The median progression-free survival following CAR2 was 8.2 months. At a median follow-up of 15.8 months post-CAR2, all pts remain alive, and three of the six pts have ongoing remissions lasting 10.8, 15, and 28 months post-CAR2.
Among the 4 pts who had allo-SCT in the intervening time between CAR1 and CAR2, 1 pt (Ph-like ALL; brexu-cel for both CAR1 and CAR2) remains in an ongoing remission at 28 months post-CAR2, while the other 3 pts relapsed at a median of 5.8 months (range, 1.8–7) post-CAR2.
Of the remaining 2 pts, 1 with allo-SCT before CAR1 is in an ongoing remission at 15 months post-CAR2, and 1 pt with no allo-SCT is in an ongoing remission at 10.8 months post-CAR2.
Conclusions
Retreatment with CD19-directed CAR T cell therapy is a feasible salvage strategy for adult pts with R/R B-ALL.
DISCLOSURES
Monika Kulasekaran, MD: No relevant conflicts of interest to declare.